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OBJECTIVE—Skeletal muscle–speciﬁc LPL knockout mouse
(SMLPL
/) were created to study the systemic impact of
reduced lipoprotein lipid delivery in skeletal muscle on insulin
sensitivity, body weight, and composition.
RESEARCH DESIGN AND METHODS—Tissue-speciﬁc insu-
lin sensitivity was assessed using a hyperinsulinemic-euglycemic
clamp and 2-deoxyglucose uptake. Gene expression and insulin-
signaling molecules were compared in skeletal muscle and liver
of SMLPL
/ and control mice.
RESULTS—Nine-week-old SMLPL
/mice showed no differences
in body weight, fat mass, or whole-body insulin sensitivity, but older
SMLPL
/ mice had greater weight gain and whole-body insulin
resistance. High-fat diet feeding accelerated the development of
obesity. In young SMLPL
/ mice, insulin-stimulated glucose up-
take was increased 58% in the skeletal muscle, but was reduced in
white adipose tissue (WAT) and heart. Insulin action was also
diminished in liver: 40% suppression of hepatic glucose production
in SMLPL
/ vs. 90% in control mice. Skeletal muscle triglyceride
was 38% lower, and insulin-stimulated phosphorylated Akt (Ser473)
was twofold greater in SMLPL
/ mice without changes in IRS-1
tyrosine phosphorylation and phosphatidylinositol 3-kinase activity.
Hepatic triglyceride and liver X receptor, carbohydrate response
element–binding protein, and PEPCK mRNAs were unaffected in
SMLPL
/ mice, but peroxisome proliferator–activated receptor
(PPAR)- coactivator-1 and interleukin-1 mRNAs were higher,
and stearoyl–coenzyme A desaturase-1 and PPAR mRNAs were
reduced.
CONCLUSIONS—LPL deletion in skeletal muscle reduces lipid
storage and increases insulin signaling in skeletal muscle without
changes in body composition. Moreover, lack of LPL in skeletal
muscle results in insulin resistance in other key metabolic tissues
and ultimately leads to obesity and systemic insulin resistance.
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L
ipoprotein lipase (LPL) (European Commission
no. 3.1.1.34) is a key enzyme in lipid metabolism
and is described as a “gatekeeper” for its role in
partitioning lipoprotein-derived free fatty acids
(FFAs) between tissues (1). Once hydrolyzed, the lipopro-
tein-derived FFAs are available for uptake and use by
extrahepatic tissues for either storage or oxidation. LPL is
most abundant in heart, adipose tissue, and skeletal mus-
cle (2,3). The importance of LPL in fuel partitioning and
utilization is underscored by observations that tissue-
speciﬁc perturbations in LPL activity result in dramatic
shifts in body composition and lipid and glucose metabo-
lism (4), particularly in heart and skeletal muscle.
We and others previously showed that mice with muscle-
speciﬁc lipoprotein lipase overexpression are insulin re-
sistant (5,6). Insulin resistance developed selectively in
muscle, while insulin sensitivity in the liver was not
affected. Overexpression of LPL in the skeletal muscle also
led to excessive intramyocellular lipid deposition, sugges-
tive of the relationship between lipid storage and insulin
sensitivity.
To further investigate the systemic impact of skeletal
muscle LPL (SMLPL) on lipoprotein-derived fatty acid
partitioning between tissues and insulin sensitivity, we
generated skeletal muscle–speciﬁc LPL knockout mice,
denoted SMLPL
/. We hypothesized that SMLPL is an
important interface through which lipid-derived signals
are integrated to regulate insulin signaling and that SMLPL
deletion would perturb the balance of fuel utilization not
only in skeletal muscle but also in other insulin-sensitive
tissues.
RESEARCH DESIGN AND METHODS
Animals. Studies were conducted in accordance to protocols approved by
institutional animal care and use committees (University of Colorado Denver
Anschutz Medical Campus, Pennsylvania State University). SMLPL
/ mice
were generated by the cre-lox system. Transgenic mice with ﬂoxed LPL (7)
were crossed with transgenic mice in which skeletal muscle–speciﬁc expres-
sion of cre recombinase was driven by the myosin light chain 1f gene promoter
(8). Offspring were then crossed with each other to produce mice with at least
one cre allele and either two ﬂoxed LPL alleles or two wild-type LPL alleles.
The presence of the cre transgene and either wild-type or ﬂoxed LPL was
veriﬁed by PCR.
Male 9- to 11-week-old (young) or 8- to 10-month-old (old) SMLPL
/ and
wild-type littermate control mice were housed at 20°C on a 12:12 h light:
dark photoperiod and provided standard rodent food and water ad libitum.
For high-fat (HF) diet feeding, 6-week-old SMLPL
/ and control mice were
put on an HF diet (Research Diet, 45% fat) and a 10% low-fat (LF) diet matched
for other nutrient content for 6 weeks. Unless speciﬁed, mice were anesthe-
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moethanol) after a 4-h fast.
Glucose and insulin tolerance tests. Glucose and insulin tolerance tests
were performed by bolus intraperitoneal injection of glucose (1 g/kg) or
insulin (0.75 units/kg), respectively. Blood glucose was measured from the tail
using a glucometer (OneTouch Ultra, Lifescan) at baseline (0) and 10, 20, 30,
45, 60, and 90 min after injection.
LPL activity assay. Tissues were dissected and assayed immediately.
Heparin-releasable LPL activity was measured in heart, white adipose
tissue (WAT), red skeletal muscle (soleus and red gastrocnemius), and
white skeletal muscle (white gastrocnemius) as previously described (9).
LPL activity was expressed as nanomoles of FFA per minute per gram of
tissue.
Measurement of body composition, plasma proﬁles, and tissue lipid
content. Body composition was measured on anesthetized mice by dual-
energy X-ray absorptiometry using a mouse densitometer (PIXImus2; Lunar,
Madison, WI). Blood was collected by cardiac puncture, and plasma was
stored at 80°C until further analysis. Plasma glucose was measured using the
Analox GM7 (Analox Instruments, Lunenburg, MA), FFAs were measured
using enzymatic colorimetric assays (Wako Chemicals, Richmond, VA), and
insulin was measured using a radioimmunoassay kit (Linco Research, St.
Charles, MO). Plasma cholesterol was measured on an Olympus AU400e
chemistry analyzer (Olympus America, Center Valley, PA). Plasma leptin,
adiponectin, interleukin (IL)-1, and IL-6 were measured using speciﬁc
enzyme-linked immunoassay (ELISA) kits (Alpco Diagnostics, Salem, NH).
Red skeletal muscle, liver, and heart tissue were excised, ﬂash-frozen, and
stored at 80°C until triglyceride (TG) content was measured as previously
described (10). Long-chain fatty acyl–coenzyme A (LC acyl-CoA) was ex-
tracted and puriﬁed from skeletal muscle using methods described previously
(11,12). After puriﬁcation, LC acyl-CoA fractions were dissolved in methanol/
H2O (1:1; vol/vol) and subjected to liquid chromatography/tandem MS analysis
(13). Diacylglycerol (DAG) and ceramide extraction and analysis were per-
formed as described previously (13,14). Total LC acyl-CoA, DAG, and cer-
amides are expressed as the sum of individual species.
Indirect calorimetry measurements. An open-ended indirect calorimetry
system was used to measure oxygen consumption O2 and CO2 production in
mice for the calculation of metabolic rate and respiratory quotient (15).
Animals were placed in metabolic chambers for measurements taken over at
least 2 days with free access to food and water.
Hyperinsulinemic-euglycemic clamps. This study was performed at the
Penn State Mouse Metabolic Phenotyping Center, and the procedures were
approved by the Pennsylvania State University Institutional Animal Care and
Use Committee. At 4–5 days before clamp experiments, mice were anesthe-
tized, and an indwelling catheter was inserted in the right internal jugular vein
(16). On the day of the clamp experiment, a three-way connector was attached
to the catheter to intravenously deliver solutions. After an overnight fast (15
h), a 2-h hyperinsulinemic-euglycemic clamp was conducted in awake
SMLPL
/ mice and wild-type littermates with a primed (150 mU/kg body wt)
and continuous infusion of insulin (Humulin; Eli Lilly, Indianapolis, IN) at a
rate of 2.5 mU  kg
1  min
1 to raise plasma insulin within a physiological
range. Blood samples (20 l) were collected at 20-min intervals for measure-
ment of plasma glucose concentration, and 20% glucose was infused at
variable rates to maintain glucose at basal concentrations. Basal and insulin-
stimulated whole-body glucose turnover were estimated with a continuous
infusion of [3-
3H]glucose (PerkinElmer, Boston, MA) for 2 h before the clamps
(0.05 Ci/min) and throughout the clamps (0.1 Ci/min), respectively. To
estimate insulin-stimulated glucose uptake in individual organs, 2-deoxy-D-[1-
14C]glucose (2-[
14C]-DG) was administered as a bolus (10 Ci) at 75 min after
the start of clamps. At the end of the clamps, mice were anesthetized, and
tissues were taken for biochemical analysis.
In vitro 2-deoxyglucose uptake in muscle. To measure 2-deoxyglucose
(2-DG) uptake, paired soleus were dissected from anesthetized mice and
incubated at 37°C for 30 min in oxygenated (95% O2,5 %C O 2) ﬂasks of
Krebs-Henseleit buffer (KHB) containing the following, with or without 50
U/ml insulin: 0.1% BSA, 2 mmol/l Na-pyruvate, and 6 mmol/l mannitol. After
30 min, muscles were transferred to a second ﬂask and incubated at 37°C for
20 min in KHB plus 0.1% BSA, 9 mmol/l [
14C]-mannitol, and 1 mmol/l [
3H]-2-DG
(0.053 and 3 mCi/mmol, respectively; Perkin Elmer, Boston, MA) with the
same insulin concentration. After 20 min, muscles were blotted on ice-cold
ﬁlter paper, trimmed, and freeze-clamped and then stored (80°C). Frozen
muscles were weighed and homogenized as previously described (17). The
homogenate was transferred to microfuge tubes and solubilized (1–2 h, 4°C)
with end-over-end rotation. The homogenate was centrifuged (12,000g, 12 min,
4°C) and used immediately for 2-DG uptake measurement. 2-DG uptake rate
was calculated as previously described (18).
Insulin signaling. Basal and insulin-stimulated red skeletal muscle, WAT,
and insulin-stimulated liver were collected from young anesthetized mice as
described previously (10). After a 10 units/kg dose of insulin (Humulin),
administered via the inferior vena cava, tissues were ﬂash-frozen in liquid
nitrogen and stored at 80°C until analysis. Basal liver tissues were collected
from a different set of mice that did not receive insulin.
For Western blot analysis, tissues were homogenized in cell lysis buffer
(10). A total of 50 g protein was electrophoresed on 8% or 10% precast
SDS-PAGE gels and transferred onto a PVDF membrane. Blots were probed
with antibodies for IR and IRS-1 phospho-tyrosine (P-Tyr-100), phospho-Akt
(S473), and phosphor-Akt (T308) (all from Cell Signaling) ﬁrst and then
stripped and probed again with antibodies for total IR (Santa Cruz), IRS-1
(Upstate), Akt, PTEN, and SHIP2 (Cell Signaling). Results were detected by
chemiluminescence (ECL; Amersham Biosciences, Piscataway, NJ) and visu-
alized on X-ray ﬁlms and analyzed using an HC Precision Scan Pro and
Bio-Rad Quantity One Analysis Software. An internal standard (wild-type
mouse homogenate) was used to normalize results and to control for
blot-to-blot variation.
The level of IRS-1–associated PI 3-kinase activity was determined in
muscle extracts after immunoprecipitation with IRS-1 antibody/agarose con-
jugate overnight at 4°C (19).
Quantitative real-time PCR. Red skeletal muscle, white skeletal muscle,
liver, WAT, and heart were collected from young anesthetized mice, ﬂash-
frozen, and stored at 80°C until processing. Total RNA was extracted from
homogenized tissue using both TRIZOL reagent (Invitrogen) and RNeasy Mini
Kit (Qiagen). One-step RT-PCR was performed using 50 ng total RNA with
iScript One-Step RT-PCR Kit for Probes (Bio-Rad, Hercules, CA) and TaqMan
Gene Expression Assays (ABI, Foster City, CA). For three internal reference
genes, one-step RT-PCR was performed using an iScript One-Step RT-PCR Kit
with SYBR Green (Bio-Rad). Reactions were run in duplicate on an iQ5
Real-Time PCR Detection System (Bio-Rad) along with no-template controls
per gene. The cycling conditions comprised 10-min cDNA synthesis at 50°C,
5-min reverse transcriptase inactivation at 95°C, and 45 cycles at 95°C for 10 s
and 60°C for 30 s. RNA expression data were normalized to levels of ubiquitin
C (Ubc) RNA, hypoxanthine guanine phosphoribosyl transferase 1 (Hprt1)
RNA, and actin beta (Actb) RNA using the comparative threshold cycle
method. Ubc, Hprt1, and Actb primer sets, as described in the study by
Vandesompele et al. (18a), were as follows: Ubc forward primer 5-AGGT-
CAAACAGGAAGACAGACGTA-3, Ubc reverse primer 5-TCACACCCAAGAA-
CAAGCACA-3; Hprt1 forward primer 5-AGTGTTGGATACAGGCCAGAC-3,
Hprt1 reverse primer 5-CGTGATTCAAATCCCTGAAGT-3; and Actb forward
primer 5-ATGCTCCCCGGGCTGTAT-3, Actb reverse primer 5-CATAG-
GAGTCCTTCTGACCCATTC-3.
Statistical analysis. Results are presented as means  SE. The t tests were
performed using SigmaStat 2.03 (San Rafel, CA). P 	 0.05 was considered
signiﬁcant.
RESULTS
Skeletal muscle–speciﬁc LPL ablation (SMLPL
/).
In 9- to 11-week-old SMLPL
/ mice, RT-PCR showed a
83% reduction (P 	 0.001) in LPL mRNA expression in the
red skeletal muscle, with only 50% reduction in white
skeletal muscle and no change in the heart (Fig. 1A).
Skeletal muscle LPL activity was decreased by 72% (P 	
0.001) in the predominantly red muscle ﬁbers of the soleus
and red gastrocnemius muscles (Fig. 1B). White muscle
LPL activity was 22% lower in SMLPL
/ mice and was not
statistically signiﬁcant (P 
 0.131). LPL activities in heart
and WAT were not affected.
Body composition, plasma metabolite proﬁles, and
energy balance. The reduction of LPL activity in skeletal
muscle did not alter body composition of 9- to 11-week-old
SMLPL
/ mice (Fig. 1C, left panel; Table 1). However, at
8–10 months of age, SMLPL
/ mice were heavier than
controls with most of the extra weight fat mass (Fig. 1C,
right panel).
Whole-body metabolic rate, respiratory quotient, and
energy intake were also not different between the two
groups of young mice (Table 1). After a 4-h fast, plasma
glucose, insulin, total and lipoprotein cholesterol, and FFA
levels were similar between young SMLPL
/ and control
mice, with a trend for higher TGs (P 
 0.074) in SMLPL
/
mice (Table 2). Plasma leptin, adiponectin, IL-1, and IL-6
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weeks of age (Table 2).
To determine whether high-fat feeding might accelerate
the obesity phenotype, 6-week-old SMLPL
/ mice were
subjected to the HF diet for 6 weeks (Fig. 1D). After 4
weeks on the HF diet, SMLPL
/ mice were heavier than
control mice (P 
 0.031 for 4 weeks; P 
 0.015 for 6
weeks).
Glucose tolerance and insulin tolerance tests. Al-
though blood glucose, insulin, and insulin tolerance were
not altered in chow-fed young mice (Fig. 2A and B),
SMLPL
/ mice developed glucose intolerance by 6
months of age (Fig. 2C). Moreover, HF-fed SMLPL
/ mice
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FIG. 1. A: mRNA expression of LPL in muscle tissues. LPL mRNA expression was measured in red skeletal muscle (SM-Red), white skeletal muscle
(SM-White), and heart using RT-PCR. n  3 for both SMLPL
/ and control mice. B: Tissue-speciﬁc LPL activities in young SMLPL
/ mice.
Heparin-releasable LPL activities were measured for skeletal red muscle (SM-Red), skeletal white muscle (SM-White), WAT, and heart from both
the 9- to 11-week-old SMLPL
/ and control mice. LPL activities were expressed as nanomoles of FFA per minute per gram of tissue. n  8 for
SMLPL
/ and n  10 for control mice. C: Weight, lean mass, and fat mass comparisons between young and old SMLPL
/ mice. The body weights
of young (8–9 weeks) and old (8–10 months) SMLPL
/ mice were compared. Body compositions were determined by dual-energy X-ray
absorptiometry. n  5 for both SMLPL
/ and control mice at different ages. D: Weight gain in HF-fed SMLPL
/ mice. The body weights of
6-week-old SMLPL
/ and control mice that are subjected to either HF or LF diet were monitored every 2 weeks for 6 weeks. n  6 for each group
of mice.
TABLE 1
General characterization of 9- to 11-week-old SMLPL
/ and
control mice
Control SMLPL
/
Body weight (g) 26.87  0.69 27.00  0.80
Lean mass (g) 22.1  0.5 22.2  0.7
Fat mass (g) 3.8  0.3 3.8  0.3
Percent fat 14.6  0.7 14.5  0.7
Energy intake (kcal/day) 13.43  1.68 11.92  1.59
MR (kcal  day
1  g
1 lean
body mass  0.75) 1.80  0.07 1.76  0.09
Respiratory quotient 0.89  0.02 0.92  0.02
n 
 8 for both groups of mice. MR, metabolic rate.
TABLE 2
Plasma lipids, metabolites, and cytokines in 9- to 11-week-old
SMLPL
/ and control mice
Control SMLPL
/
Glucose (mmol) 10.0  1.2 9.5  1.2
Insulin (ng/ml) 0.66  0.30 0.45  0.30
FFA (mmol/l) 0.58  0.10 0.66  0.11
Total cholesterol (mg/dl) 102  15 128  33
HDL cholesterol (mg/dl) 56  86 1  13
LDL cholesterol (mg/dl) 31  62 4  7
Triglycerides (mg/dl) 77  45 219  92
Leptin (ng/ml) 1.3  1.6 3.1  2.5
Adiponectin (mg/ml) 33  14 33  5
IL-1 (pg/ml) 28  19 20  11
IL-6 (pg/ml) 32  27 15  2
n 
 8 for glucose, insulin, and FFA measurement for both groups of
mice. n 
 6 for all other measurements.
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control mice (Fig. 2D).
Whole-body insulin sensitivity and tissue-speciﬁc
glucose metabolism. Insulin sensitivity in 9- to 11-week-
old mice was comparable between SMLPL
/ and control
mice with glucose infusion rates of 39  4 and 44  4m g
kg
1  min
1, respectively (Fig. 3A, left). Of great interest,
however, SMLPL
/ mice displayed a reduced capacity of
insulin to suppress hepatic glucose production with only
39  8% suppression (from 19.1 to 11.1 mg  kg
1  min
1)
compared to 91  8% suppression (from 20.5 to 0.4 mg 
kg
1  min
1) in the control mice (P 
 0.001) (Fig. 3A,
right). At 8–10 months, SMLPL
/ mice developed sys-
temic insulin resistance (Fig. 3B).
More surprisingly, 2-DG uptake measured at the end of
the clamp was increased in skeletal muscle of the young
SMLPL
/ mice (539  48 vs. 341  20 nmol  g
1  min
1,
P 
 0.003) but was greatly reduced in WAT (11  3 vs.
51  9n m o l g
1  min
1, P 
 0.003) and heart (1,798 
359 vs. 3,257  223 nmol  g
1  min
1, P 
 0.006) (Fig. 3C).
A trend for reduced glucose uptake was also observed in
brown adipose tissue of SMLPL
/ mice (582  90 vs.
1,552  424 nmol  g
1  min
1, P 
 0.072).
The maximal glucose transport activity in isolated so-
leus muscle was measured for both young SMLPL
/ and
control mice (Fig. 3D). In control mice, glucose transport
was increased 40% upon insulin stimulation. In SMLPL
/
mice, basal glucose transport was increased 25% com-
pared with control mice, and it was further increased 80%
upon insulin stimulation (P 
 0.01 vs. control). Thus,
skeletal muscle from young SMLPL
/ mice displayed a
higher basal glucose transport activity and was more
responsive to insulin both in vivo and ex vivo.
These ﬁndings indicated that skeletal muscle–speciﬁc
deletion of LPL in young mice increased insulin sensitivity
selectively in skeletal muscle but caused insulin resistance
in liver, heart, and adipose tissues, suggesting that recip-
rocal changes in insulin action in different tissues might be
responsible for the lack of changes in whole-body insulin
sensitivity.
Skeletal muscle TG content reduced with no change
in other lipid metabolites. To understand whether
changes in cellular and circulating lipids might underlie
the changes in insulin sensitivity in SMLPL
/ mice, we
measured TG content in skeletal muscle, liver, and heart
(Fig. 4A). SMLPL
/ mice showed a 40% reduction (P 

0.045) in skeletal muscle TG, with no difference in liver
TG. Yet there were no differences in intramuscular total
LC acyl-CoA, total DAG, or total ceramide levels in
SMLPL
/ and control mice (Fig. 4B). Heart TG was not
different (P 
 0.126) in SMLPL
/ mice (Fig. 4A).
Increased insulin signaling in skeletal muscle. Be-
cause glucose uptake in the skeletal muscle was higher in
the SMLPL
/ mice during the hyperinsulinemic clamp,
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FIG. 2. Glucose tolerance test and insulin tolerance test of SMLPL
/ mice. Time courses of blood glucose levels in young SMLPL
/ and control
mice after intraperitoneal injection of 1 g/kg glucose (A) or 0.75 units/kg insulin (B) are shown. Time courses are also shown of blood glucose
levels in 6-month-old SMLPL
/ and control mice after intraperitoneal injection of 1 g/kg glucose (C) and for 12-week-old SMLPL
/ and control
mice that have been subjected to different diet for 6 weeks (D). n  6 for the glucose tolerance test, and n  5 for SMLPL
/; n  4 for control
mice in the insulin tolerance test.
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insulin-signaling cascade. Surprisingly, there were no dif-
ferences in the total levels of IR, IRS-1, Akt, insulin-
stimulated tyrosine phosphorylation of the insulin
receptor or IRS-1, or PI 3-kinase activation (Fig. 5A–C).
However, we observed a nearly twofold increase in net
insulin-stimulated Ser473 Akt activation (P 	 0.01) upon
insulin stimulation (Fig. 5D) in the red muscle of the
SMLPL
/ mice. Full activation of Akt also requires the
phosphorylation of threonine 308 of the activation loop in
Akt by PDK1 (20). SMLPL
/ mice showed a 40% increase
in Thr308 Akt phosphorylation under basal conditions
(P 
 0.05), while insulin induced a similar 50% increase of
Thr308 Akt phosphorylation in SMLPL
/ and control
mice (Fig. 5E). The levels of two lipid phosphatases
known to modify Akt phosphorylation (PTEN and SHIP2)
(21,22) were unchanged in SMLPL
/ mice (Fig. 5F).
Examination of the insulin-signaling cascade in liver and
WAT showed no differential activation (data not shown).
Speciﬁcally, and unlike the response to insulin in red
skeletal muscle, the level of insulin-stimulated Akt phos-
phorylation was not different in the liver or the WAT of the
two groups of mice.
Gene regulation in skeletal muscle and liver. Quanti-
tative real-time PCR (qRT-PCR) was performed to exam-
ine whether the loss of SMLPL affected important genes
involved in lipid, glucose, and fatty acid metabolism in the
skeletal red muscle (Fig. 6A). In eight representative genes
examined, the mRNA expression levels of peroxisome
proliferator–activated receptor (PPAR), PPAR, tumor
necrosis factor (TNF)-, carnitine palmitoyl transferase-2,
CD36, acetyl–coenzyme A carboxylase 2, and ﬁbroblast
growth factor 21 were not altered. Interestingly, the mRNA
level of PPAR coactivator (PGC)-1 was increased by 60%
in the skeletal red muscle of SMLPL
/ mice (P 
 0.01).
Similar qRT-PCR was performed on the liver of
SMLPL
/ and control mice. A total of 13 representative
genes were compared (Fig. 6B), and none of the gluconeo-
genic genes examined (PEPCK and glucose-6-phospha-
tase) showed differential expression. IL-1 expression was
increased by 64% (P 
 0.034), and PGC-1 expression was
increased by 73% (P 
 0.005) in SMLPL
/ liver. On the
other hand, the hepatic gene expression levels for SCD-1
and PPAR mRNA were signiﬁcantly lower (69 and 57%,
respectively) in SMLPL
/ mice (P 
 0.049 and P 
 0.001,
respectively).
A comparison of 10 representative genes in WAT
showed a trend for an increase in genes related to inﬂam-
matory pathways: CD68, IL-1, IL-6, and TNF-; however,
these changes were not statistically signiﬁcant (data not
shown).
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FIG. 3. Whole-body insulin sensitivity and tissue-speciﬁc glucose uptake in vivo in the SMLPL
/ and control mice. A: Steady-state whole-body
glucose infusion rate during hyperinsulinemic-euglycemic clamps and hepatic insulin action as the percent suppression of basal hepatic glucose
production during the clamps for young SMLPL
/ mice. n  5 for both SMLPL
/ and control mice. B: Steady-state whole-body glucose infusion
rate during hyperinsulinemic-euglycemic clamps for old SMLPL
/ mice. n  5 for both SMLPL
/ and control mice. C: Tissue-speciﬁc glucose
uptake. Insulin-stimulated glucose uptake in skeletal muscle (gastrocnemius, SM), WAT, brown adipose tissue (BAT), and heart were measured
by injecting a bolus of 2-[
14C]-DG during the clamp. n  5 for SMLPL
/ and n  6 for control mice. D: Insulin-stimulated glucose transport in
soleus muscle of SMLPL
/ mice (n  3 for both SMLPL
/ and control mice). DPM, disintegrations per minute.
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Lipid partitioning between tissues is important to insulin
action, energy balance, and the regulation of body weight
and composition. The normal physiology of lipid and
lipoprotein fuel partitioning is controlled by the transport
and uptake of adipose tissue–derived FFA and lipoprotein-
derived TG fatty acids. Tissue-speciﬁc changes in the
regulation of LPL in obese subjects may play an important
role in nutrient partitioning when energy intake exceeds
energy expenditure (23–27). Thus, the ability to selectively
modify LPL in skeletal muscle and/or adipose tissue may
inﬂuence body weight and composition. The SMLPL
/
mice were created to provide a model to study how
reduced lipid partitioning to skeletal muscle inﬂuences
insulin-sensitive tissues and the potential role in regulating
body weight, body composition, and whole-body insulin
sensitivity.
SMLPL
/ mice show a transition of phenotypes be-
tween young and old animals. At a young (9–11 weeks)
age, body weight and percent fat were unchanged com-
pared with WT controls. With aging, both body weight and
percent fat were increased in SMLPL
/ and systemic
insulin resistance developed. The transition of the pheno-
type was accelerated by feeding the young SMLPL
/ mice
with HF diets. Such information suggests an increased
propensity that lipid storage develops and that accompa-
nies lower lipid deposition in skeletal muscle.
The deletion of LPL in skeletal muscle results in two
distinct patterns of clinical and biochemical abnormalities in
young mice. The ﬁrst is an increase in insulin sensitivity in
skeletal muscle. The second is the decrease of insulin sensi-
tivity in liver and other tissues. The present data suggest that
skeletal muscle, and LPL in particular, acts as an important
buffer against excess lipid storage but cannot protect against
the ultimate development of obesity or insulin resistance.
Despite no change in body composition in young SMLPL
/
mice or whole-body glucose disposal during the hyperinsu-
linemic clamp, closer inspection of individual tissues
revealed that insulin-stimulated 2-DG uptake was signif-
icantly greater in skeletal muscle, whereas other insulin-
sensitive tissues (WAT, heart) showed remarkable
reductions in insulin-stimulated glucose uptake.
The increase in insulin-stimulated glucose uptake in
skeletal muscle of young SMLPL
/ mice was associated
with reduced TG accumulation in skeletal muscle and
increased basal and insulin-stimulated Akt phosphoryla-
tion. Interestingly, there were no differences in the accu-
mulation of other metabolic intermediates such as LC
acyl-CoAs, ceramides, and DAG in skeletal muscle. Unex-
pectedly, the signiﬁcant effect on increased Akt phosphor-
ylation in SMLPL
/ mice was not associated with greater
IRS-1 or PI 3-kinase activity. This suggests that LPL may
play a role in regulating other lipid-derived factors that
affect Akt phosphorylation in skeletal muscle.
Because the total PTEN and SHIP2 levels were not
different in SMLPL
/ versus control mice, it is unlikely
that these two negative regulators of Akt activity contrib-
ute to the increased Akt phosphorylation we observed in
SMLPL
/ mice. Increased Akt phosphorylation at Ser473
has been associated with the mammalian target of rapa-
mycin(mTOR)-rictor complex (28,29). Because there was
no change in the Ser–IRS-1 phosphorylation (an mTOR
target), it suggests that there may be other regulators of
Akt in SMLPL
/ mice. For example, phosphorylation of
Akt at Thr308 and Ser473 can be inhibited by direct
binding of two different proteins: carboxyl-terminal mod-
ulator protein or TRB3 (30,31). Also, a pH domain leucine-
rich repeat protein phosphatase (PHLPP) has also been
shown to speciﬁcally dephosphorylate Ser-473 and inacti-
vate Akt (32). Interestingly, insulin-stimulated Akt Thr308
phosphorylation was unaffected in SMLPL
/ mice, sug-
gesting that there might be different combination of path-
ways affecting Akt activation. In subsequent studies, it will
be important to identify which of these possible mediators
might serve as the link between reduced LPL-mediated
lipid uptake and deposition and enhanced Akt activation in
our SMLPL
/ mice.
Increased insulin-stimulated glucose uptake and lower
TG in skeletal muscle of young SMLPL
/ mice also
suggest that the loss of LPL activity in skeletal muscle in
SMLPL
/ mice creates a preference for glucose rather
than TG-rich lipoproteins for fuel. Because plasma li-
poprotein TG and liver TG were not statistically different
for SMLPL
/ and control mice, more TG-rich lipoprotein
TG may be processed in liver, WAT, or heart. Noting that
LPL activity in WAT tissue was only marginally increased
in SMLPL
/ mice and the fat mass remained the same as
control mice, WAT tissue could be compensating for the
loss of LPL in skeletal muscle by enhancing lipoprotein-
dependent lipid uptake and turnover. However, at 9–11
weeks, there was no increase in TG storage in the heart, an
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It is very likely at this stage of phenotypic development
that the heart increased fatty acid oxidation in response to
the reduced lipid partitioning to skeletal muscle.
Despite increased skeletal muscle insulin sensitivity,
SMLPL
/ mice also displayed hepatic insulin resistance,
as indicated by the reduced capacity to suppress hepatic
glucose production upon insulin stimulation. However, TG
content in the liver of SMLPL
/ mice was not increased.
Gene expression in the liver of SMLPL
/ mice was mostly
unchanged, whereas PGC-1 and IL-1 expression was
modestly increased, and PPAR- and SCD-1 mRNA levels
reduced in the liver of SMLPL
/ mice. The increase in
IL-1 expression suggests a possible role of this cytokine
in mediating insulin resistance in liver. However, when we
measured the plasma IL-1 and IL-6 levels in SMLPL
/
mice, there was no indication that the circulating cytokine
levels were elevated in the plasma of the mice.
The downregulation of PPAR- and SCD-1 in liver of the
SMLPL
/ mice is consistent with the liver not storing
excessive TG in the SMLPL
/ mice. SCD-1 catalyzes the
desaturation of saturated fatty acyl-CoAs and is regulated
by liver X receptor (LXR) (33). LXR gene expression,
however, was not different in SMLPL
/ mice. SCD-1 has
also been identiﬁed along with several other genes in-
volved in lipogenesis as a direct target of PPAR- in liver.
Furthermore, SCD-1 plays a pivotal role in the regulation
of hepatic and plasma lipoprotein TG concentrations, and
SCD-1–deﬁcient mice are usually protected against hyper-
triglyceridemia (34). Interestingly, SMLPL
/ mice had a
borderline increase of plasma TG, despite the lower SCD-1
mRNA in liver. Moreover, PPAR- is usually associated
with greater liver TG storage, and hepatic overexpression
of this transcription factor leads to steatosis (35). Given
that both PPAR- and SCD-1 mRNAs are lower and
PGC-1 is higher in the livers of SMLPL
/ mice, the liver
might respond to the excess delivery of FFAs by maintain-
ing a higher rate of gluconeogenesis during insulin infu-
sion in the clamp study.
To summarize and conclude, the loss of SMLPL reduced
skeletal muscle TG and increased insulin sensitivity. De-
spite the lack of change in whole-body insulin sensitivity at
a young age, insulin resistance in WAT, liver, and heart
was already evident. In the skeletal muscle of young
SMLPL
/ mice, insulin signaling at the level of Akt was
increased, suggesting that LPL-derived lipids inﬂuence
both basal and insulin-stimulated Akt activation. Because
the reduction of LPL-dependent lipid processing in skele-
tal muscle must result in the partitioning of TG-rich
lipoproteins to other tissues, over time this promotes
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